Alkermes plc has released data from its schizophrenia portfolio that will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference that will be held from April 2-6 in Florence Italy. Read More »
Sarepta Therapeutics has announced that its New Drug application (NDA) for eteplirsen will be reviewed by the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System (PCNS) Drug Advisory Committee on April 25. Read More »
Cigna has announced that Cigna Hospital Care, the company’s new group hospital indemnity insurance policy, will be available starting in April. Read More »
Allergan has announced that it has submitted an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for the approval of market Paclitaxel Protein-Bound Particles for Injectable Suspension, 100 mg/vial. Read More »
Meritain Health, an Aetna subsidiary, has announced a collaboration with Banner Health Network (BHN) and Aetna Whole Health, which provides members with access to coordinated care administered by physicians and facilities in accountable care networks nationwide. Read More »
Surescripts has provided new data showing that more than 48,000 providers in New York have turned to technology to help fight prescription fraud and abuse. Read More »
Biota Pharmaceuticals has announced the completed sale of its assets relating to its broad spectrum antibiotic program to a new subsidiary of Spero Therapeutics LLC. Read More »
Discount Drug Mart Inc. recently hosted its biannual pharmacists meeting and promoted a get-out-the vote campaign with funding from the NACDS’ RxIMPACT. Read More »
McKesson announced this week that it has launched its disaster recovery service that will help health care organizations uphold their mission-critical capabilities when disasters strike. Read More »
Walgreens Boots Alliance has announced that it has exercised warrants for the purchase of 22,696,912 common stock shares of AmerisourceBergen Corp. for a total payment of $1.17 billion. Read More »
The American Society of Health-System Pharmacists (ASHP) has published “Extemporaneous Formulations for Pediatric, Geriatric and Special Needs Patients” to aid in the treatment of patients who require medication dosages and forms that are not available commercially. Read More »
Pfizer has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for XELJANZ (tofacitinib citrate) for review. Read More »
The U.S. Food and Drug Administration (FDA) has issued a draft guidance that will help the pharmaceutical industry in its development of approved generic opioid drugs that contain abuse-deterrent formulations (ADF). Read More »
Pharmacy benefit managers could save labor unions, employers, government programs and consumers upwards of $654 billion during the next ten years, according to a new campaign launched by the Pharmaceutical Care Management Association (PCMA), the national group representing pharmacy benefit managers, or PBMs. Read More »
A new Kaiser Permanente study documents that stroke patients are more likely to take their prescribed medication when it is delivered to their home, proving patients want convenience. Read More »
AstraZeneca today announced the results from the SOCRATES trial that examined the effectiveness of Brilinta/Brilique (ticagrelor) 90 mg tablets meant to be taken twice a day compared to aspirin100 mg once per day in patients suffering from acute ischemic stroke or transient ischemic attack (TIA). Read More »
The American Society of Health-System Pharmacists (ASHP) has published a step-by-step guide that is intended to help clinical coordinators and managers thrive in the workplace. Read More »
The U.S. Food and Drug Administration has approved Cinqair (reslizumab) for the treatment of severe asthma in combination with other asthma medicines in patients 18 years of age or older. Read More »
The U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab), which was designed for the treatment of adults with moderate-to-severe plaque psoriasis. Read More »
The U.S. Food and Drug Administration (FDA) announced this week the approval of Anthim (oblitoxaximab) injection for the treatment of inhalational anthrax to be used in combination with antibacterial drugs. Read More »
Alerts Sign-up
